Matches in SemOpenAlex for { <https://semopenalex.org/work/W904360218> ?p ?o ?g. }
- W904360218 abstract "Abstract Aim: microRNAs (miRs) have been implicated in many malignancies. Our aim was to identify specific miRNAs that can predict risk of relapse in pediatric acute lymphoblastic leukemia (ALL) patients treated on BFM protocols, better than the current risk group stratification. Currently, the main method for risk group stratification is based on the amount of minimal residual disease (MRD) assessed at specific time points by real time quantitative PCR (RQ-PCR). Material and methods: Following microRNA expression analysis performed on 48 bone marrow samples at diagnosis, we focused on several miRs that correlated with at least 3 of the established prognostic markers in ALL to be validated in a cohort of 138 B-lineage ALL samples. Of the miRs studied, down regulated miR-151-5p and miR-451 and upregulated miR-1290 significantly correlated with outcome. Results: Low expression of miR-151-5p, miR-451 or of both together resulted in significantly worse relapse free survival (RFS) (56%, 63% and 47%, respectively) compared to RFS rates when either or both miRs were highly expressed (80%, 78% and 78%, respectively) (p=0.007, 0.042 and 0.002, respectively). High expression of miR-1290 resulted in worse RFS compared to those that expressed low levels (54% versus 81%; p=0.014). When combining the 3 miRs, a patient expressing low levels of both miRs and/or high levels of miR-1290 had a RFS of 54% (p=0.004). Furthermore, the expression of the 3 miRs could distinguish within the TEL-AML1 negative cohort two groups; one with 80% and the other with 44% RFS (p=0.004). Multivariate Cox regression analysis identified low expression of both miRs and/or high expression of miR-1290 as an independent prognostic marker in the PCR-MRD non-high risk cohort. Patients expressing abnormal levels of the 3 miRs had a 4.47-fold increased risk for relapse (p=0.037). Deletion of IKZF1 gene is a known adverse prognostic marker in B-lineage ALL. In 85 patients, IKZF1 status was analyzed and 9 patients were found to harbor the deletion. The expression of the 3 miRs could still identify an adverse group of patients with 69% RFS within the group with no deletion (p=0.004). When adding IKZF1 and TEL-AML1 status to the Multivariate analysis in addition to PCR-MRD, the expression of the 3 miRs remained a significant independent marker with a 24 fold increased risk for relapse (p=0.011). Figure 1 Figure 1. Conclusion: Our results identify the combination of miR-151-5p, miR-451 and miR-1290 as a novel biomarker for outcome in pediatric B-lineage ALL patients, already at time of diagnosis. This may lead to improved risk group stratification and enable early therapeutic intervention that may result in better RFS. Disclosures No relevant conflicts of interest to declare." @default.
- W904360218 created "2016-06-24" @default.
- W904360218 creator A5005347976 @default.
- W904360218 creator A5012074919 @default.
- W904360218 creator A5013556787 @default.
- W904360218 creator A5017872011 @default.
- W904360218 creator A5020546928 @default.
- W904360218 creator A5025706257 @default.
- W904360218 creator A5043037950 @default.
- W904360218 creator A5043164298 @default.
- W904360218 creator A5044760977 @default.
- W904360218 creator A5052153842 @default.
- W904360218 creator A5053455919 @default.
- W904360218 creator A5056816227 @default.
- W904360218 creator A5062833816 @default.
- W904360218 creator A5065448452 @default.
- W904360218 creator A5070729528 @default.
- W904360218 creator A5078067153 @default.
- W904360218 creator A5078188302 @default.
- W904360218 creator A5080987519 @default.
- W904360218 creator A5081832303 @default.
- W904360218 creator A5087639742 @default.
- W904360218 creator A5091089371 @default.
- W904360218 date "2014-12-06" @default.
- W904360218 modified "2023-09-27" @default.
- W904360218 title "Prediction of Relapse By microRNA Expression in Pediatric B-Lineage Acute Lymphoblastic Leukemia" @default.
- W904360218 doi "https://doi.org/10.1182/blood.v124.21.3793.3793" @default.
- W904360218 hasPublicationYear "2014" @default.
- W904360218 type Work @default.
- W904360218 sameAs 904360218 @default.
- W904360218 citedByCount "0" @default.
- W904360218 crossrefType "journal-article" @default.
- W904360218 hasAuthorship W904360218A5005347976 @default.
- W904360218 hasAuthorship W904360218A5012074919 @default.
- W904360218 hasAuthorship W904360218A5013556787 @default.
- W904360218 hasAuthorship W904360218A5017872011 @default.
- W904360218 hasAuthorship W904360218A5020546928 @default.
- W904360218 hasAuthorship W904360218A5025706257 @default.
- W904360218 hasAuthorship W904360218A5043037950 @default.
- W904360218 hasAuthorship W904360218A5043164298 @default.
- W904360218 hasAuthorship W904360218A5044760977 @default.
- W904360218 hasAuthorship W904360218A5052153842 @default.
- W904360218 hasAuthorship W904360218A5053455919 @default.
- W904360218 hasAuthorship W904360218A5056816227 @default.
- W904360218 hasAuthorship W904360218A5062833816 @default.
- W904360218 hasAuthorship W904360218A5065448452 @default.
- W904360218 hasAuthorship W904360218A5070729528 @default.
- W904360218 hasAuthorship W904360218A5078067153 @default.
- W904360218 hasAuthorship W904360218A5078188302 @default.
- W904360218 hasAuthorship W904360218A5080987519 @default.
- W904360218 hasAuthorship W904360218A5081832303 @default.
- W904360218 hasAuthorship W904360218A5087639742 @default.
- W904360218 hasAuthorship W904360218A5091089371 @default.
- W904360218 hasConcept C104317684 @default.
- W904360218 hasConcept C126322002 @default.
- W904360218 hasConcept C143998085 @default.
- W904360218 hasConcept C145059251 @default.
- W904360218 hasConcept C150194340 @default.
- W904360218 hasConcept C18431079 @default.
- W904360218 hasConcept C203014093 @default.
- W904360218 hasConcept C2778461978 @default.
- W904360218 hasConcept C2779823535 @default.
- W904360218 hasConcept C2780007613 @default.
- W904360218 hasConcept C2781107101 @default.
- W904360218 hasConcept C2909962599 @default.
- W904360218 hasConcept C54355233 @default.
- W904360218 hasConcept C71924100 @default.
- W904360218 hasConcept C72563966 @default.
- W904360218 hasConcept C86803240 @default.
- W904360218 hasConceptScore W904360218C104317684 @default.
- W904360218 hasConceptScore W904360218C126322002 @default.
- W904360218 hasConceptScore W904360218C143998085 @default.
- W904360218 hasConceptScore W904360218C145059251 @default.
- W904360218 hasConceptScore W904360218C150194340 @default.
- W904360218 hasConceptScore W904360218C18431079 @default.
- W904360218 hasConceptScore W904360218C203014093 @default.
- W904360218 hasConceptScore W904360218C2778461978 @default.
- W904360218 hasConceptScore W904360218C2779823535 @default.
- W904360218 hasConceptScore W904360218C2780007613 @default.
- W904360218 hasConceptScore W904360218C2781107101 @default.
- W904360218 hasConceptScore W904360218C2909962599 @default.
- W904360218 hasConceptScore W904360218C54355233 @default.
- W904360218 hasConceptScore W904360218C71924100 @default.
- W904360218 hasConceptScore W904360218C72563966 @default.
- W904360218 hasConceptScore W904360218C86803240 @default.
- W904360218 hasLocation W9043602181 @default.
- W904360218 hasOpenAccess W904360218 @default.
- W904360218 hasPrimaryLocation W9043602181 @default.
- W904360218 hasRelatedWork W2020563679 @default.
- W904360218 hasRelatedWork W2026077325 @default.
- W904360218 hasRelatedWork W2082833993 @default.
- W904360218 hasRelatedWork W2166086147 @default.
- W904360218 hasRelatedWork W2254658962 @default.
- W904360218 hasRelatedWork W2399192209 @default.
- W904360218 hasRelatedWork W2516507829 @default.
- W904360218 hasRelatedWork W2552716992 @default.
- W904360218 hasRelatedWork W2574098295 @default.
- W904360218 hasRelatedWork W2583602832 @default.
- W904360218 hasRelatedWork W2762949291 @default.
- W904360218 hasRelatedWork W2791708054 @default.